Vimarsana
Biggest News Aggregation in the World

Page 12 - Linical Evolution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Linical Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Linical Evolution Today - Breaking & Trending Today

Mission Therapeutics moves kidney disease drug to phase 2 after FDA approval - Vimarsana News

Mission Therapeutics moves kidney disease drug to phase 2 after FDA approval

Mission Therapeutics, a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to proceed with a phase 2 trial for its kidney treatment MTX652.

Neurological diseases focus of Pharmakure's alliance with Malaysian university - Vimarsana News

Neurological diseases focus of Pharmakure's alliance with Malaysian university

Clinical-stage pharma company, PharmaKure which develops precision medicine for Alzheimer’s Disease and other neurological diseases has announced a collaboration agreement with one of the largest comprehensive universities in Malaysia.

HIV pathology data now reaching investigators within hours - Vimarsana News

HIV pathology data now reaching investigators within hours

The AIDS and Cancer Specimen (ACSR), a biorepository of specimens collected from persons living with HIV (PLWH) has today (December 12) announced it is using software from Proscia that can provide near real-time access to pathology data to investigators around the world.

How Clario is improving clinical trials: 'Therapies that hold immense promise may never see the light of day' - Vimarsana News

How Clario is improving clinical trials: 'Therapies that hold immense promise may never see the light of day'

Dr. Michael O’Neal, chief medical officer at Clario, believes that many drugs ultimately fail due to common operational and data challenges that could, and should, be corrected.

Interview: Enthought - the trials and tribulations of AI - Vimarsana News

Interview: Enthought - the trials and tribulations of AI

OSP had a great conversation with Mike Connell, chief operating officer, at Enthought. The discussion centered around aritificial intelligence (AI) which have been the buzzwords in pharma and a number of other industries for at least the last year.